31 January 2019  
EMA/CHMP/917551/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Orencia 
abatacept 
On 31 January 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending changes to the terms of the marketing authorisation for the medicinal product 
Orencia. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma EEIG. 
The CHMP adopted a new indication for Orencia 50, 87.5 and 125 mg solution for injection in pre-filled 
syringe as follows: 
“Polyarticular juvenile idiopathic arthritis 
Orencia in combination with methotrexate is indicated for the treatment of moderate to severe 
active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older 
who have had an inadequate response to previous DMARD therapy. 
Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with 
methotrexate is inappropriate.” 
The CHMP also adopted a change to an existing indication for Orencia 250 mg powder for concentrate for 
solution for infusion as follows:2 
“Polyarticular juvenile idiopathic arthritis 
Orencia in combination with methotrexate is indicated for the treatment of moderate to severe 
active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 6 years of age and older 
who have had an insufficient inadequate response to other DMARDs including at least one 
TNF inhibitorprevious DMARD therapy. 
Orencia can be given as monotherapy in case of intolerance to methotrexate or when 
treatment with methotrexate is inappropriate.” 
For information, the full indications for Orencia 50, 87.5 and 125 mg solution for injection in pre-filled 
syringe will be as follows: 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
“Rheumatoid arthritis 
Orencia, in combination with methotrexate, is indicated for: 
• 
• 
the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who 
responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic 
drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha 
inhibitor. 
the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis 
not previously treated with methotrexate. 
A reduction in the progression of joint damage and improvement of physical function have been 
demonstrated during combination treatment with abatacept and methotrexate. 
Psoriatic arthritis 
Orencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active 
psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including 
MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not 
required. 
Polyarticular juvenile idiopathic arthritis 
Orencia in combination with methotrexate is indicated for the treatment of moderate to severe 
active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older 
who have had an inadequate response to previous DMARD therapy. 
Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with 
methotrexate is inappropriate.” 
For information, the full indications for Orencia 250 mg powder for concentrate for solution for infusion will 
be as follows: 
“Rheumatoid arthritis 
Orencia, in combination with methotrexate, is indicated for: 
• 
• 
the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who 
responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic 
drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha 
inhibitor. 
the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis 
not previously treated with methotrexate. 
A reduction in the progression of joint damage and improvement of physical function have been 
demonstrated during combination treatment with abatacept and methotrexate. 
Psoriatic Arthritis 
Orencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active 
psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including 
MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not 
required. 
Orencia  
EMA/CHMP/917551/2019 
Page 2/3 
 
  
  
Polyarticular juvenile idiopathic arthritis 
Orencia in combination with methotrexate is indicated for the treatment of moderate to severe 
active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 6 years of age and older 
who have had an inadequate response to previous DMARD therapy. 
Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with 
methotrexate is inappropriate.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
Orencia  
EMA/CHMP/917551/2019 
Page 3/3 
 
  
  
